Medikamentöse Intervention bei Herzrhythmusstörungen

  • D. Kalusche

Zusammenfassung

Medikamentöse Interventionen bei Herzrhythmusstörungen sollen im folgenden unter 2 Aspekten besprochen werden:
  • Akutinterventionen bei in der Regel tachykarden, hämodynamisch bedeutsamen Herzrhythmusstörungen. Bei den meisten dieser Arrhythmien ist die medikamentöse Intervention Therapie der ersten Wahl und absolut unbestritten;

  • Chronische Interventionen zur dauerhaften Unterdrückung von Ektopien oder zur permanenten prophylaktischen Beeinflussung potentieller Reentrykreise, um das Auftreten bedrohlicher anhaltender Tachykardien zu verhindern.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Akhtar M, Shenasa M, Tchou PJ, Jazayeri M (1987) Role of electrophysiologic studies in supraventricular tachycardia. In: Brugada P, Wellens HJJ (eds) Cardiac arrhythmias: where to go from here? Mount Kisco, New York, Futura Publishing Co pp 233Google Scholar
  2. 2.
    Amlie JP, Storstein L (1980) Effects of autonomic blockade on the inotropic and electrophysiologic response to digitoxin in the intact dog. J Cardiovasc Pharmacol 2: 55PubMedGoogle Scholar
  3. 3.
    Andresen D, Tietze U, von Leitner ER, Lehmann HU, Thormann I, Wessel HJ, Schröder R (1980) Spontanvariabilität tachykarder Rhythmusstörungen, Z Kardiol 59: 214Google Scholar
  4. 4.
    Bastian BC, McFarland PW, McLauchlan JH et al. (1980) A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J 100: 1017PubMedGoogle Scholar
  5. 5.
    Bayes de Luna A, Coumel P, Leclercq JF (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151PubMedGoogle Scholar
  6. 6.
    Belhassen B, Horowitz LN (1984) Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol 54: 1131PubMedGoogle Scholar
  7. 7.
    Belhassen B, Viskin S (1993) What is the drug of choice for the acute termination of paroxysmal supraventricular tachycardia: verapamil, adenosine, triphosphate, or adenosine? PACE 16: 1735PubMedGoogle Scholar
  8. 8.
    Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, the Multicenter Post-Infarction Research Group (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69: 250PubMedGoogle Scholar
  9. 9.
    Bigger JR, Jaffe C (1971) The effect of bretylium tosylate on the electrophysiological properties of ventricular muscle and Purkinje fibers. Am J Cardiol 27: 82PubMedGoogle Scholar
  10. 10.
    Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58: 496PubMedGoogle Scholar
  11. 11.
    Brugada P, Brugada J, Mont L, Smeets J, Andries E (1991) A new approach to the differential diagnosis of a regular tachycardia. Circulation 83:1649PubMedGoogle Scholar
  12. 12.
    Burkart F, Pfisterer M, Kiowski W, Burckhardt P, Follath F (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol 16: 1711PubMedGoogle Scholar
  13. 13.
    Calkins H, Sousa J, El-Atassi R, et al. (1991) Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachyardias during a single electrophysiologic test. Engl J Med 324: 1612Google Scholar
  14. 14.
    Camm AJ, Garratt CJ (1991) Adenosine and supraventricular tachycardia. N Engl J Med 325: 1621PubMedGoogle Scholar
  15. 15.
    Campbell TJ (1990) Proarrhythmic actions of antiarrhythmic drugs: a review. Aust NZ J Med 20: 275Google Scholar
  16. 16.
    The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227Google Scholar
  17. 17.
    The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327: 227Google Scholar
  18. 18.
    CAST investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406Google Scholar
  19. 19.
    Ceremuzynski L, Kleczar E, Krzeminska-Pakula M et al. (1992) Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 20: 1056PubMedGoogle Scholar
  20. 20.
    Chamberlain DA, Jewitt DE, Julian DG, Campbell RW, Boyle DM, Shanks RG (1980) Oral mexiletine in high-risk patients after myocardial infarction. Lancet II: 1324Google Scholar
  21. 21.
    Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P (1992) Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 70: 44APubMedGoogle Scholar
  22. 22.
    Collaborative Group (1971) Phenytoin after recovery from myocardial infarction: Controlled trial in 568 patients. Lancet 2: 1055Google Scholar
  23. 23.
    Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm. Circulation 82: 1106PubMedGoogle Scholar
  24. 24.
    Coumel P, Leclercq JF, Attuel P, Lavallee JP, Flammang D (1979) Autonomic influences in the genesis of atrial arrhythmias: Atrial flutter and fibrillation of vagal origin. In: Narula OS (ed) Cardiac arrhythmic Electrophysiology, diagnosis and management. William & Wilkins, Baltimore London, p 243Google Scholar
  25. 25.
    Coumel P, Leclercq JF, Attuel P (1982) Paroxysmal atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. AB Hässle, Mölndal, p 158Google Scholar
  26. 26.
    Danilo P Jr. (1979) Mexiletine. Am Heart J 97: 399PubMedGoogle Scholar
  27. 27.
    Davison R, Parker M, Atkinson AJ (1982) Excessive serum lidocaine levels during maintainance infusions: mechanisms and prevention. Am Heart J 104: 203PubMedGoogle Scholar
  28. 28.
    De Paola AAV, Horowitz LN, Morganroth J, Senior S, Spielman SR, Greenspan AM, Kay HR (1987) Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol 9:163PubMedGoogle Scholar
  29. 29.
    Dias VC, Weir SJ, Ellenbogen KA (1992) Pharmacokinetics and pharmocodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Circulation 86: 1421PubMedGoogle Scholar
  30. 30.
    DiMarco JP, Sellers TD, Lerman BB, Greenberg ML, Berne RM, Belardinelli L (1985) Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 6: 417PubMedGoogle Scholar
  31. 31.
    Echt DS, Liebson PR, Mitchell LB et al. (1991) Mortality and morbity in patients receiving encaiinide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 324: 781PubMedGoogle Scholar
  32. 32.
    Edvardsson N, Olsson SB (1982) Outpatient electroconversion of chronic atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. AB Hässle, Mölndal, p 242Google Scholar
  33. 33.
    Eichelbaum M, Spannbrucker N, Dengler AJ (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics. Europ J Clin Pharmacol 16:189Google Scholar
  34. 34.
    Eldar M, Griffin JC, van Hare GF, Witherell C, Bhandari A, Benditt D, Scheinmann MM (1992) Combined use of betaadrenergic agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 20: 830PubMedGoogle Scholar
  35. 35.
    Elfner R, Kollmeier W, Lentz A et al. (1986) Dosis-Wirkungs-Beziehung von N-Prajmaliumbitartrat unter Plasmaspiegelkontrolle. Z Kardiol 75: 402PubMedGoogle Scholar
  36. 36.
    Escourbet B, Coumel P, Poirier JM et al. (1985) Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations. Am J Cardiol 55: 696Google Scholar
  37. 37.
    Ettinger PO, Wu CF, De la Cruz C, Weisse AB, Ahmed SS, Regan TJ (1978) Arrhythmias and the „holiday heart“: alcohol-associated cardiac rhythm disorders. Am Heart J 95: 555PubMedGoogle Scholar
  38. 38.
    Fleckenstein A (1970) Die Zügelung des Myocardstoffwechsels durch Verapamil: Angriffspunkte und Anwendungsmöglichkeiten. Arzneimittelforsch 20: 131Google Scholar
  39. 39.
    Fleckenstein A (1975) Fundamentale Herz- und Gefäßwirkungen Ca-antagonistischer Koronartherapeutika. Med Klin 70: 1665PubMedGoogle Scholar
  40. 40.
    Fogoros RN (1993) The effect of the implantable cardioverter defibrillator on sudden death and on total survival. PACE 16: 506PubMedGoogle Scholar
  41. 41.
    Gouaux JL, Ashman B (1947) Auricular fibrillation with aberration simulating ventricular paroxysmal tachycardia. Am Heart J 34: 366PubMedGoogle Scholar
  42. 42.
    Greene HL (1989) The Efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. Progress in Cardiovascular Diseases XXXI, 5: 319Google Scholar
  43. 43.
    Greene HL, Graham EL, Werner JA et al. (1983) Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 2: 1114PubMedGoogle Scholar
  44. 44.
    Guerot C, Coste A, Valere PE, Tricot R (1973) L’epreuve a l’Ajmaline dans le diagnostic du bloc auriculoventriculaire paroxystique. Arch Mal Coeur 66: 1241PubMedGoogle Scholar
  45. 45.
    Haverkamp W, Hördt M, Chen X, Hindricks G, Willems S, Kottkamp H, Rotman B, Brunn J, Borggrefe M, Breithardt G (1993) Torsades de pointes. Z Kardiol 82: 763PubMedGoogle Scholar
  46. 46.
    Hohnloser SH, Zabel M, van de Loo A, Klingenheben T, Just H (1992) Efficacy and safety of Sotalol in patients with complex ventricular arrhythmias. Int J Cardiol 37: 283PubMedGoogle Scholar
  47. 47.
    Hohnloser SH, van de Loo A, Baedecker F, Hablawetz E, Just H (1994) Effektivität und Sicherheit von Sotalol versus Chinidin zur Konversionstherapie von persistierendem Vorhofflimmern: Ein prospektiver randomisierter Vergleich. Z Kardiol 83 (Suppl 1): 13Google Scholar
  48. 48.
    Homburger H, Antoni H (1974) Elektrophysiologische Effekte von N-Propyl-Ajmalinium-hydrogentartrat (NPAB) am isolierten Säugetiermyokard. In: Antoni H, Effert S (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart New York, S 180–195Google Scholar
  49. 49.
    Hony RM, Ritchie WT, Thomson WAR (1930) The action of adenosine upon the human heart. Q J Med 23: 485Google Scholar
  50. 50.
    Hood MA, Smith WM (1992) Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-cross-over trial. Am Heart J 123:1543PubMedGoogle Scholar
  51. 51.
    Hugenholtz PG, Hagemeijer F, Lubsen J, Glazer B, van Durme JP, Bogaert MG (1978) One year follow-up in patients with persistent ventricular dysrhythmias after myocardial infarction treated with aprindine or placebo. Excerpta Med 572:8Google Scholar
  52. 52.
    Impact Research Group (1984) International mexilltine and placebo antiarrhythmic coronary trial, a report on arrhythmia and other findings. J Am Coll Cardiol 4: 1148Google Scholar
  53. 53.
    Jackman, WM, Beckman KJ, McClelland JH et al. (1992) Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 327: 31Google Scholar
  54. 54.
    Jähnchen E, Trenk D (1983) Pharmakokinetische Prinzipien und spezielle Pharmakokinetik der Antiarrhythmika. In: Lüderitz B (Hrsg) Herzrhythmusstörungen. Handbuch der Inneren Medizin, Bd IX/1. Springer, Berlin Heidelberg New York Tokyo, S 167Google Scholar
  55. 55.
    Jenzer HR, Hagemeijer F (1976) Quinidine syncope: torsades de pointes with low quinidine plasma concentrations. Europ J Cardiol 4: 447Google Scholar
  56. 56.
    Jerwell A, Lange-Nielsen F (1957) Congenital deaf-mutism, functional heart disease with prolongation auf the Q-T interval and sudden death. Am Heart J 54: 59Google Scholar
  57. 57.
    Jezer A, Oppenheimer BS, Schwartz SP (1933) The effect of adenosine cardiac irregularities in man. Am Heart J 9: 252Google Scholar
  58. 58.
    Kalusche D, Stockinger J, Betz P, Roskamm H (1994) Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhofflimmern — Konversion und 12-Monats-Follow-up -Ein randomisierter Vergleich. Z Kardiol 83 (Suppl 5): 109PubMedGoogle Scholar
  59. 59.
    Kalusche D, Behroz A, Betz P, Roskamm H (1991) Aussagekraft diastolischer Flußmessungen mittels PW-Doppler nach Konversion von Vorhofflimmern (AA) im Hinblick auf die Erhaltung des Sinusrhythmus (SR). Z Kardiol 80 (Suppl 3): 43Google Scholar
  60. 60.
    Kalusche D (im Druck) Antikoagulation und Aggregationshemmer bei Herzerkrankungen (3). In: Roskam H, Reindell H (Hrsg) Herzkrankheiten, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  61. 61.
    Karagueuzian HS, Singh BN, Mandel WJ (1987) Antiarrhythmic drugs: mode of action, pharmacokinetic properties, and clinical application. In: Mandel WJ (ed) Cardiac arrhythmias. Lippincott JB, Philadelphia London, p 697Google Scholar
  62. 62.
    Kay GN, Epstein AE, Dailey SM, Plumb VJ (1993) Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovas Electrophysiol 4: 371Google Scholar
  63. 63.
    Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppart M (1991) Linkage of cardiac arrhythmia, the long QT syndrome, and Harvey ras-1 gene. Science 252: 704PubMedGoogle Scholar
  64. 64.
    Kindwall KE, Brown J, Josephson ME (1988) Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol 61:1279PubMedGoogle Scholar
  65. 65.
    Klein, LS, Miles WM, Hackett FK, Zipes DP (1992) Catheter ablation of ventricular tachycardia using radiofrequency techniques in patients without structural heart disease. Herz 17: 179PubMedGoogle Scholar
  66. 66.
    Leclercq JF, Chouty F, Denjoy I, Coumel P, Slama R (1992) Flecainide in quinidine-resistant atrial fibrillation. Am J Cardiol 70: 6Google Scholar
  67. 67.
    Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P (1994) Short-coupled variant of torsade de pointes. Circulation 89: 206PubMedGoogle Scholar
  68. 68.
    Lindsay BD, Chung MK, Gamache MC, Luke RA, Schechtman KB, Osborn JL, Cain ME (1993) Therapeutic end points for the treatment of atrioventricular node reentrant tachycardia by catheter-guided radiofrequency current. J Am Coll Cardiol 22: 733PubMedGoogle Scholar
  69. 69.
    Mackenzie J (1914) Diseases of the heart, 3rd edn. Oxford Medical Publications, London, pp 211Google Scholar
  70. 70.
    Manz M, Mletzko R, Jung W, Lüderitz B (1992) Electrophysiologic and hemodynamic effects of lidocaine and ajmahne in the management of sustained ventricular tachycardia. Europ Heart J 13:1123Google Scholar
  71. 71.
    Manz M, Wagner WL, Lüderitz B (1988) Combination of mexiletine and Sotalol in complex ventricular arrhythmias. N Trends Arrhyt 6 (Suppl): 35Google Scholar
  72. 72.
    Manz M, Lüderitz B (1988) Vergleichende Untersuchung von Ajmalin und Lidocain bei ventrikulären Tachyarrhythmien. In: Lüderitz B, Antoni H (Hrsg) Perspektiven der Arrhythmiebehandlung. Springer, Berlin Heidelberg New York Tokyo, S3Google Scholar
  73. 73.
    Marcus FI (1983) Drug interactions with amiodarone. Am Heart J 106: 924PubMedGoogle Scholar
  74. 74.
    Mason JW (1993) A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329: 445PubMedGoogle Scholar
  75. 75.
    Mclntosh-Yellin NL, Drew BJ, Scheinman MM (1993) Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia. J Am Coll Cardiol 22: 741Google Scholar
  76. 76.
    Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystowsky EN (1988) Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 319 5: 257PubMedGoogle Scholar
  77. 77.
    Morady F, Baerman JM, DiCarlo LA, DeBuitleir M, Krol RB, Wahr DW (1985) A prevalent misconception regarding wide-complex tachycardias. JAMA 254: 2790PubMedGoogle Scholar
  78. 78.
    Morganroth J, Michelson EL, Horowitz LN, Josephson ME, Pearlmann AS, Dunkman B (1978) Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 58: 408PubMedGoogle Scholar
  79. 79.
    Moss AJ, Schwartz PJ (1982) Delayed repolarization (QTor QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 51: 85PubMedGoogle Scholar
  80. 80.
    Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ (1991) The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 84:1136PubMedGoogle Scholar
  81. 81.
    Nademanee K, Piwonka RW, Singh BN, Hershman JM (1989) Amiodarone and thyroid function. Progr Cardiovasc Dis XXXI 6: 427Google Scholar
  82. 82.
    Neuss H, Horn HG, Mitrovic V, Schlepper M (1979) Die Wirkung des Calcium-Antagonisten D 600 bei Knotentachykardien. Z Kardiol 68: 643Google Scholar
  83. 83.
    Nisam S, Mower M, Moser S (1991) ICD clinical update: first decade, initial 10.000 patients. PACE 14: 255PubMedGoogle Scholar
  84. 84.
    Nguyen PT, Scheinman MM, Seger J (1986) Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 74: 340PubMedGoogle Scholar
  85. 85.
    Pantridge JF (1974) Prehospital coronary care. Br J Heart 36: 233Google Scholar
  86. 86.
    Pearl WR (1982) Massive lidocaine overdose. Am Heart J 103: 1083PubMedGoogle Scholar
  87. 87.
    Peters T, Ross D, Duffield A, Luxton M, Harper R, Hurt D, Sloman G (1978) Effect on survival after myocardial infarction of longterm treatment with phenytoine. Br Heart J 40: 1356Google Scholar
  88. 88.
    Platia EV, Estes NAM, Heine DL, Griffith L, Garan H, Ruskin JN, Reid PR (1985) Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 55: 956PubMedGoogle Scholar
  89. 89.
    Podrid PJ, Schoeneberger A, Lown B (1980) Congestive heart failure caused by oral disopyramide. N Engl J Med 302: 614PubMedGoogle Scholar
  90. 90.
    Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB (1989) The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapie: a dangerous imbalance in the risk-benefit ratio. Am Heart J 118: 433PubMedGoogle Scholar
  91. 91.
    Probst P (1975) Die Indikation zur prophylaktischen Schrittmacherimplantation bei hochgradigen atrioventrikulären Überleitungsstörungen. Z Kardiol 64: 926PubMedGoogle Scholar
  92. 92.
    Rankin AC, Oldroyd KG, Chong E, Rae AP, Cobbe SM (1989) Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J 62:195PubMedGoogle Scholar
  93. 93.
    Ricci DR, Orlick AE, Reitz BA, Mason JW, Stinson EB, Harrison DC (1978) Depressant effect of digoxin on atrioventricular conduction in man. Circulation 57: 898PubMedGoogle Scholar
  94. 94.
    Rizzon P, de Biase M, Favale S, Visani L (1987) Class Ib agents lidocaine mexiletine, tocainide, phenytione. Europ Heart J8 (Suppl A): 21Google Scholar
  95. 95.
    Roden DM, Woosley RL, Primm RK (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111: 1088PubMedGoogle Scholar
  96. 96.
    Romano C, Gemme G, Pongiglione R (1963) Aritmie cardiache rare dell’eta’ pediatrica. La Clinica Pediatrica 45:656PubMedGoogle Scholar
  97. 97.
    Ryden L, Amman K, Conradson TB, Hofvendahl S, Mortensen O, Smedgard P (1980) Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100:10Google Scholar
  98. 98.
    Sami M, Kraemer H, Harrison DC, Houston N, Shimasaki C, de Busk RF (1980) A new method for evaluating antiarrhythmic drug efficacy. Circulation 62: 1172PubMedGoogle Scholar
  99. 99.
    Schaumlöffel E (1974) Pharmakokinetische Studien mit radioaktiv markiertem N-n-Propyl-Ajmalinium-Hydrogentartrat an Ratte und Mensch. In: Antoni H, Effert S (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart NewYork, S209Google Scholar
  100. 100.
    Schlepper M (1987) Propafenone, a review of its profile. Europ Heart J 8 (Suppl A): 27Google Scholar
  101. 101.
    Schmidt G, Barthel P, Ulm K, Herb H, Kreuzberg L, Goedel-Meinen L, Baedeker W, Blömer H (1991) Antiarrhythmische Therapiekontrolle mittels Holter-Monitoring. In: Schmidt G (Hrsg) Medikamentöse Behandlung des Postinfarktpatienten nach CAST. Steinkopff, Darmstadt, S 55Google Scholar
  102. 102.
    Schmidt G, Ulm K, Goedel-Meinen L et al. (1986) Kriterien zur Sicherung antiarrhythmischer Effekte im Langzeit-EKG unter Berücksichtigung des Kontrollintervalls. Z Kardiol 75 (Suppl 4): 62Google Scholar
  103. 103.
    Schwartz PJ, Periti M, Malliani A (1975) The long QT-syndrome. Am Heart J 89: 378PubMedGoogle Scholar
  104. 104.
    Schwartz JB, Keefe EL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elminiation kinetics during chronic oral administration. Am Heart J 104:198PubMedGoogle Scholar
  105. 105.
    Selzer A, Wray HW (1964) Quinidine syncope. Paroxysmal ventricular fibrillation during treatment of chronic atrial arrhythmias. Circulation 30: 17PubMedGoogle Scholar
  106. 106.
    Sethi KK, Manoharan S, Mohan JC, Gupta MP (1986) Verapamil in idiopathic ventricular tachycardia of right bundle branch block morphology: Oberservations during electrophysiologic and exercise testing. PACE 9: 8PubMedGoogle Scholar
  107. 107.
    Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 755Google Scholar
  108. 108.
    Singh BN, Vaughan-Williams EM (1970) A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3676. Brit J Pharmacol 39: 675Google Scholar
  109. 109.
    Singh BN, Vaughan Williams EM (1970) The effect of amiodarone, a new anti-anginal drug on cardiac muscle. Brit J Pharmacol 39: 657Google Scholar
  110. 110.
    Slater W, Lampert S, Podrid PJ, Lown B (1988) Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 61: 349PubMedGoogle Scholar
  111. 111.
    Smith MS, Verghese CP, Shand DG, Pritchett ELC (1983) Phamacokinetic and pharmocodynamic effects of diltiazem. Am J Cardiol 51: 1369PubMedGoogle Scholar
  112. 112.
    Stanton MS, Prystowsky EN, Fineberg NS, Miles WN, Zipes DP, Heger JJ (1987) Incidence of ventricular tachycardia and ventricular fibrillation as proarrhythmic effects during treatment of ventricular arrhythmia. J Am Coll Cardiol 9: 245AGoogle Scholar
  113. 113.
    Steinbeck G, Bach P, Haberl R (1986) Electrophysiologic and antiarrhythmic efficacy of oral Sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol 8: 949PubMedGoogle Scholar
  114. 114.
    Steinbeck G, Dolwina R, Bach P (1986) Glykoside für paroxysmales Vorhofflimmern? Z Kardiol 75 (Suppl I): 24Google Scholar
  115. 115.
    Stewart RB, Bardy GH, Greene HL (1986) Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 104: 766PubMedGoogle Scholar
  116. 116.
    Storey GC, Holt DW (1982) High performance liquid chromatographic measurements of amiodarone and desethyl amiodarone in plasma or serum at concentrations obtained following a single 400 mg dose. J Chromatograph 245: 377Google Scholar
  117. 117.
    Task Force of the Working Group on Arrhythmias of the European Society of Cardiology (1990) CAST and beyond implications of the cardiac arrhythmia suppression trial. Eur Heart J 11:194Google Scholar
  118. 118.
    Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD (1987) Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 10: 633PubMedGoogle Scholar
  119. 119.
    Thormann J, Schlepper M (1983) Hämodynamische Auswirkungen kardialer Arrhythmien. In: Lüderitz B (Hrsg) Herzrhythmusstörungen. Handbuch der Inneren Medizin, Bd IX/1. Springer, Berlin Heidelberg New York Tokyo, S 355Google Scholar
  120. 120.
    Trappe HJ, Brugada P, Talajic M, Lezaun R, Wellens HJJ (1989) Herzrhythmusstörungen: Prognose und Verlauf von Patienten mit Kammertachykardien oder Kammerflimmern ohne koronare Herzkrankheit. Z Kardiol 78:500PubMedGoogle Scholar
  121. 121.
    Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, Stern S (1988) Treatment of torsades de pointes with magnesium sulfate. Circulation 77: 392PubMedGoogle Scholar
  122. 122.
    Vaughan Williams EM (1991) Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol 31: 123PubMedGoogle Scholar
  123. 123.
    Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886PubMedGoogle Scholar
  124. 124.
    Vrobel TR, Miller PE, Mostow ND, Rakita L (1989) A general overview of amiodarone toxicity: its prevention, detection, and management. Progr Cardiovasc Dis XXXI 6:393Google Scholar
  125. 125.
    Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H (1986) Kumulation von Metoprolol im Plasma unter der Therapie mit Propafenon. Z Kardiol 75 (Suppl I): 25Google Scholar
  126. 126.
    Ward EC (1964) A new familial cardiac syndrom in children. J Irish Med Ass 54: 103Google Scholar
  127. 127.
    Wegscheider K, Andresen D, von Leitner ER, Schröder R (1982) Neue Methode zur Erfassung der Spontanvariabilität einfacher und komplexer Rhythmusstörungen in Abhängigkeit von der Häufigkeit ihres Auftretens. Z Kardiol 71: 179Google Scholar
  128. 128.
    Weidner A, Engels J (1979) Nebenwirkungen rhythmisierender Substanzen. In: Antoni H, Bender F, Gerlach E, Schlepper M (Hrsg) Herzrhythmusstörungen. Schattauer, Stuttgart New York, S 387Google Scholar
  129. 129.
    Weinberg BA, Miles Wm, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C, Zipes DP (1993) Five-year follow-up 589 patients treated with amiodarone. Am Heart J 125:109PubMedGoogle Scholar
  130. 130.
    Wellens HJJ, Bar FW, Lie KI (1978) The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 64: 27PubMedGoogle Scholar
  131. 131.
    Wellens HJJ, Bar FW, Dassen WRM, Brugada P, Vanagt EJ, Farre J (1980) Effect of drugs in the Wolff-Parkinson-White syndrome. Am J Cardiol 46: 665PubMedGoogle Scholar
  132. 132.
    Wellens HJJ, Bar FW, Vanagt EJ, Brugada P, Farre J (1981) The differentiation between ventricular tachycardia and supraventricular tachycardia with aberrant conduction: The value of the 12-lead-electrocardiogram. In: Wellens HJJ, Kulbertus HE (eds) What’s new in electrocardiography? Martinus Nijhoff Publishing, The Hague, pp 184Google Scholar
  133. 133.
    Wellens HJJ, Brugada P (1989) Treatment of cardiac arrhythmias: when, how and where? J Am Coll Cardiol 14: 1417PubMedGoogle Scholar
  134. 134.
    Wilkinson PR, Rees JR, Storey GC, Holt DW (1984) Amiodarone prolonged elimination following cessation of chronic therapy. Am Heart J 107: 787PubMedGoogle Scholar
  135. 135.
    Winkle RA (1978) Antiarrhythmic drug effect mimicked by spontaneous variability of ventricular ectopy. Circulation 57: 1116PubMedGoogle Scholar
  136. 136.
    Zipes DP (1988) Proarrhythmic events. Am J Cardiol 61: 70AGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • D. Kalusche

There are no affiliations available

Personalised recommendations